Stock INVA INNOVIVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
14.99 USD -1.12% Intraday chart for Innoviva, Inc. +2.04% -6.55%
Apr. 24 Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 CI
Mar. 04 Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
AQ
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
BU
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
MT
North American Morning Briefing : Stock Futures -2-
DJ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.
CI
Innoviva: Q4 Earnings Snapshot
AQ
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M
MT
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BU
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics
CI
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer
AQ
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing
MT
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
AQ
Innoviva: Q3 Earnings Snapshot
AQ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.
CI
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
BU
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M
MT
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INVA Stock
  4. News Innoviva, Inc.